Chemotherapy Market is Increasing prevalence of cancer is set to Growth at a CAGR of 7.50% Near Future

Pune, India, May 2023, MRFR Press Release/- Market Research Future has Published a Cooked Research Report on the Global Chemotherapy Market.

Market Highlights

The Global Chemotherapy Market is estimated to be valued at USD 15.72 Billion by 2032 and is expected to register a CAGR of 7.50% during the forecast period (2023-2032).

The alkylating agents segment dominated the global chemotherapy market, by drug class, and is projected to reach USD 20,360.32 Million and projected to be the fastest-growing segment during the forecast period.

Americas dominated the market, accounting for the largest share of the market in 2018, and the regional market is expected to register a CAGR of 10.88% during the review period. The European market was the second largest in 2018. The market is projected to reach USD 18,292.73 Million, with Germany being the leading market.

Segment Analysis

The Global Chemotherapy Market has been segmented on the basis of drug class, indication, route of administration, end user, and region. On the basis of drug class, the market has been divided into alkylating agents, antimetabolites, mitotic inhibitors, antitumor antibiotic, and topoisomerase inhibitors. The alkylating agents segment held the majority market share in 2018 and anticipated to be the fastest growing, followed by the mitotic inhibitors segment.

On the basis of indication, the market has been divided into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, leukemia, lymphoma, and ovarian cancer. The lung cancer segment accounted for the larger market share in 2018. However, the breast cancer segment is expected to exhibit higher CAGR during the forecast period.

On the basis of route of administration, the market has been divided into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. The intravenous segment accounted for the larger market share in 2018. However, the oral segment is expected to exhibit higher CAGR during the forecast period.

On the basis of end user, the market has been divided into specialty centers, hospitals & clinics, and others. The specialty centers segment accounted for the larger market share in 2018 and expected to exhibit higher CAGR during the forecast period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Chemotherapy Market Research Report

Market Players

Market Research Future (MRFR) recognizes Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US) as the key players in the global chemotherapy market.

Regional Analysis

Geographically, the global chemotherapy market has been segmented into the Americas, Europe, Asia-Pacific, and Middle East & Africa. As per MRFR analysis, the Americas was the largest market for chemotherapy in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The increasing prevalence of cancer is a major driving factor for the growth of the chemotherapy market in Europe. Germany accounted for the largest market share of 27.07% in 2018 and projected to register a CAGR of 11.45% during the forecast period.

Key Findings of the Study:

• The Global Chemotherapy Market is projected to reach over USD 15.72 Billion by 2032 and is expected to register a CAGR of 7.50% during the forecast period (2023-2032).

• Americas accounted for the largest market share with the US being the major contributor to the growth of the market.

• The breast cancer indication segment is projected to register the highest CAGR of 11.94% during the forecast period.

• Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies.